argenx registers Phase 2 trial of empasiprubart for Guillain-Barré syndromeSep 16Trial updateargenxempasiprubart
Annexon reports Q2 2026 results, sets tanruprubart BLA for fourth quarterAug 12Quarterly updateAnnexon, Inc.
Sign inSign in